ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2157

Nationwide Estimated Prevalence of SLE: United States Population-Based Study, 2001-2011

KimNgan P. Nguyen1, Eric Yen2, Ning Li3 and Ram R. Singh2, 1David Geffen School of Medicine, UCLA, LOS ANGELES, CA, 2UCLA, Los Angeles, CA, 3Biomathematics, University of California, Los Angeles, Los Angeles, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Lupus and SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

In the published literature, the prevalence rates of SLE have widely varied by as much as 12-fold over the years. This is likely due to the variability in study populations (region and race/ethnicity), case definitions (self-report, ICD codes, physician diagnosis, ACR criteria, and SLICC criteria), and case ascertainment sources (case registry, hospital, specialists, laboratory report, US renal database, death certificate, and insurance claims data). Most studies, thus far, covered relatively small population size such as a city, county or state or Medicaid database. To the best of our knowledge, there are no studies on SLE prevalence that cover the total population of the United States (US). Although, elegant reports from 5 CDC registries covering several counties in 5 states provide valuable information on SLE prevalence, there is an important unmet need to estimate the national prevalence of SLE in the US.

Methods:

We used ambulatory physician visits in the US derived from the 2001-2011 National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS) database to determine encounters that represent SLE, using ICD-9 code 710.0. Using the number of prior visits per patient, we estimated the number of patients with SLE from the visit encounters. STATA was then used to determine the mean proportion and 95% confidence interval.

Results:

The overall prevalence rate of SLE is 122/100,000 persons in the US. The annual prevalence of SLE increased from 104.2/100,000 in 2001 to 164.3/100,000 in 2011. The period prevalence of SLE from 2001-2011 is 14-fold higher in females (224/100,000) than males (16/100,000). Non-Hispanic black persons had the highest prevalence of SLE (206/100,000), followed by Hispanics (118/100,000), and non-Hispanic white persons (87/100,000). There were substantial variations in SLE prevalence by geographic regions: persons living in the West had the highest prevalence (143/100,000), followed by South (129/100,000), Northeast (120/100,000), and Midwest (90/100,000).

Conclusion:

Analysis of national survey data across the US reveals an increasing trend in the prevalence of SLE over the last decade, which may reflect an increased recognition of SLE, changes in physician’s coding practices, or an actual increase in the prevalence. Lack of verification of SLE diagnosis by rheumatologists is a major limitation of this study, especially since there is discordance even among rheumatologists as to what constitutes a diagnosis of lupus. Nevertheless, our data shows regional and demographic differences in SLE prevalence in communities across the US. The female: male ratio of 14:1 in SLE prevalence is higher than in previous studies, which might be due to a lack of recognition of SLE in males by primary care physicians or lack of men visiting clinics that were surveyed by NAMCS or NHAMCS. Like in previous studies, SLE prevalence was higher in black persons than in white persons. Racial/ethnic differences in SLE prevalence may also be due to racial/ethnic differences in individuals who visit clinics that were surveyed or due to lack of entry in the race/ethnicity column by persons of certain race/ethnicity.


Disclosure: K. P. Nguyen, RRF Medical and Graduate Student Preceptorship, 9; E. Yen, None; N. Li, None; R. R. Singh, RRF Medical and Graduate Student Preceptorship Award, 9.

To cite this abstract in AMA style:

Nguyen KP, Yen E, Li N, Singh RR. Nationwide Estimated Prevalence of SLE: United States Population-Based Study, 2001-2011 [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/nationwide-estimated-prevalence-of-sle-united-states-population-based-study-2001-2011/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nationwide-estimated-prevalence-of-sle-united-states-population-based-study-2001-2011/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology